Form 4: ImmunityBio CAO Lauer's RSU Vesting and Share Sale

ImmunityBio's Chief Accounting Officer, Regan Lauer, reported the vesting of restricted stock units and a subsequent sale of shares for tax obligations.

Summary

• Regan J. Lauer, Chief Accounting Officer of ImmunityBio, Inc. (IBRX), reported transactions related to her beneficial ownership.
• On February 22, 2026, 4,065 restricted stock units (RSUs) vested, converting into an equal number of common shares.
• Concurrently, 1,673 shares were disposed of at a price of $8.7 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Lauer's direct beneficial ownership of ImmunityBio common stock is 115,875 shares.
• The vesting commencement date for this RSU award was February 22, 2024, with vesting scheduled over three years.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction related to executive compensation, reflecting the normal course of RSU vesting and tax withholding. It is neither significantly positive nor negative for the company's operational or financial outlook.

Positives

• The vesting of 4,065 restricted stock units indicates the achievement of performance or time-based milestones, reflecting continued value creation for the executive.
• The executive's continued beneficial ownership of 115,875 shares aligns her interests with long-term shareholder value.

Negatives

• A portion of the vested shares (1,673 shares) was sold to cover tax obligations, resulting in a reduction of direct beneficial ownership.

Future Outlook

The RSU award's vesting schedule indicates future vesting events on the first, second, and third anniversaries of the February 22, 2024 commencement date, subject to continued service.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related share sales are standard practice for executive compensation, reflecting a common mechanism for aligning executive incentives with company performance and retention. This filing does not provide broader industry insights.

Comparison to Industry Standards

• StockSavvy.ai notes that the practice of granting Restricted Stock Units (RSUs) with multi-year vesting schedules is a common compensation strategy across the biotechnology and pharmaceutical industries, similar to practices at companies like Amgen, Gilead Sciences, and Moderna.
• The automatic withholding of shares to cover tax obligations upon vesting is also a standard, widely adopted procedure to manage executive compensation in a tax-efficient manner, consistent with global benchmarks for executive equity awards.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes slightly increases the public float but is a routine event with minimal impact on overall share price or ownership structure. The executive's continued ownership aligns interests.
• Employees: The RSU vesting demonstrates the company's commitment to its equity compensation plans, which can positively influence employee morale and retention, particularly for key executives.

Next Steps

• Future vesting events for the remaining RSU award on the first, second, and third anniversaries of February 22, 2024.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are standard for executive compensation and do not typically indicate a change in the company's fundamental performance or outlook. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate based solely on this filing.

Keywords

ImmunityBio, IBRX, Regan Lauer, Chief Accounting Officer, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, share sale, tax withholding, beneficial ownership